SBRT combined with Nimotuzumab followed by Tislelizumab
2023152
Phase 2 small_molecule active
Quick answer
SBRT combined with Nimotuzumab followed by Tislelizumab for Nasopharyngeal Cancinoma (NPC) is a Phase 2 program (small_molecule) at The First People's Hospital of Lianyungang with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The First People's Hospital of Lianyungang
- Indication
- Nasopharyngeal Cancinoma (NPC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active